December 8, 2025BloodOpen Access

Teclisito: Low-intensity teclistamab in the outpatient setting for Relapsed/Refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Compassionate use program shows 91% response rate in relapsed/refractory multiple myeloma, highlighting manageable adverse events.

Low-dose teclistamab resulted in a complete response in 52% of patients, indicating effective treatment for relapsed/refractory multiple myeloma.
The median progression-free survival was 12 months, with adverse events mostly mild and manageable, facilitating outpatient care.
This compassionate use program treated patients who previously had multiple therapy lines, emphasizing access in resource-limited settings.
Overall survival at 12 months was estimated at 80.8%, suggesting a promising therapy option amidst limited availability in low-income regions.

Leal et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Compassionate use program shows 91% response rate in relapsed/refractory multiple myeloma, highlighting manageable adverse events.

Low-dose teclistamab resulted in a complete response in 52% of patients, indicating effective treatment for relapsed/refractory multiple myeloma.
The median progression-free survival was 12 months, with adverse events mostly mild and manageable, facilitating outpatient care.
This compassionate use program treated patients who previously had multiple therapy lines, emphasizing access in resource-limited settings.
Overall survival at 12 months was estimated at 80.8%, suggesting a promising therapy option amidst limited availability in low-income regions.

Leal et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark